文献速递临床试验与 GCP

伊伐布雷定预防非心脏手术后心肌损伤(PREVENT-MINS试验):一项随机对照试验的研究方案

Ivabradine for prevention of myocardial injury after noncardiac surgery (PREVENT-MINS trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2025-11-21

PREVENT-MINS是一项在波兰26家医院开展的多中心、平行组、盲法、安慰剂对照试验,计划纳入2500例≥45岁、接受非心脏手术且至少有一项心肌损伤危险因素的患者,按1:1随机接受伊伐布雷定5 mg口服每日两次(术前1小时开始,共7天)或安慰剂,主要结局为随机化后30天内非心脏手术后心肌损伤(MINS),由独立专家裁定。

要点

  • 围手术期心动过速增加非心脏手术后心肌损伤风险,而围手术期β受体阻滞剂虽可预防心肌损伤却增加死亡和卒中风险。
  • 伊伐布雷定是一种选择性降低心率的药物,可能提供更安全的替代选择。
  • 主要结局为随机化后30天内MINS,由独立专家裁定,分析采用意向性治疗原则。

核心结论

  • 该试验旨在确定在合并或存在动脉粥样硬化性疾病风险、接受非心脏手术的患者中,围手术期给予伊伐布雷定在预防非心脏手术后心肌损伤(MINS)方面是否优于安慰剂。

研究设计与样本

  • 多中心、平行组、盲法、安慰剂对照试验,在波兰26家医院开展。
  • 计划纳入2500例年龄≥45岁、接受非心脏手术且至少有一项心肌损伤危险因素的患者。
  • 参与者按1:1比例随机接受伊伐布雷定5 mg口服每日两次(术前1小时开始,共7天)或安慰剂。

主要发现

  • 主要结局为随机化后30天内的MINS,由独立专家裁定。
  • 次要结局包括30天时的血管并发症、死亡率、血流动力学和生活质量。
  • 其他三级结局和1年结局将评估长期心血管和手术并发症。

关键数值与推荐

  • 主要结局分析采用卡方检验,结果以未调整的相对危险度(RR)及95%置信区间(CI)和P值呈现。
  • 分析遵循意向性治疗原则。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myocardial injury is a major cause of death after noncardiac surgery and is associated with long-term cardiovascular outcomes. Perioperative tachycardia increases this risk. Although perioperative beta blockers prevent myocardial injury, they increase the risk of death and stroke, which analyses suggest is due to a significant increase in hypotension. Ivabradine, a selective heart rate-lowering drug, may offer a safer alternative. The primary objective of the PREVENT-MINS trial is to determine whether perioperative administration of ivabradine is superior to placebo for the prevention of myocardial injury after noncardiac surgery (MINS) in patients with or at risk of atherosclerotic disease having noncardiac surgery. METHODS: The PREVENT-MINS trial is a multicentre, parallel-group, blinded, placebo-controlled trial conducted in 26 hospitals in Poland. It will enroll 2500 patients aged ≥ 45 years undergoing noncardiac surgery with at least one risk factor for myocardial injury. Participants will be randomized in a 1:1 ratio to receive ivabradine 5 mg orally twice daily for 7 days starting 1 h before surgery or placebo. The primary outcome is MINS within 30 days after randomization; independent experts will adjudicate this outcome. Secondary outcomes include vascular complications, mortality, haemodynamics, and quality of life at 30 days. Additional tertiary and 1-year outcomes will assess long-term cardiovascular and surgical complications. Analyses will follow an intention-to-treat approach. For the primary outcome, a chi-squared test will be conducted, with results presented as unadjusted relative risk (RR) accompanied by 95% confidence intervals (CIs) and p-values. DISCUSSION: This trial will generate high-quality, generalizable data due to its large population and rigorous design, including blinding. Moreover, it will be one of the first large-scale trials specifically focused on preventing MINS. TRIAL REGISTRATION: ClinicalTrials.gov NCT05279651. Registered on 4 March 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Szczeklik W, Fronczek J, Putowski Z, et al. Ivabradine for prevention of myocardial injury after noncardiac surgery (PREVENT-MINS trial): study protocol for a randomized controlled trial. Trials. 2025. PMID: 41272750. doi:10.1186/s13063-025-09087-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。